Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno Studio Randomizzato per Confrontare l'Efficacia e la Sicurezza dell'Infusione Prolungata e Intermittente dei Beta-lattamici nei Pazienti Pediatrici Critici. (PEBBLE)

3 novembre 2026 aggiornato da: Semmelweis University

Protocollo di uno studio randomizzato, a due bracci di superiorità, per confrontare l'efficacia e la sicurezza dell'infusione prolungata e intermittente di beta-lattamici in pazienti pediatrici critici.

The goal of this clinical trial is to examine the success and safety of administering certain antibiotics (beta-lactams) given in a longer 3-hour infusion to children (0-17 years) who are critically ill and have severe infection.

The main question it aims to answer is:

Is the longer infusion more effective than the conventional short-term (0.5-hour-long) infusion? Researchers will compare the 3-hour-long infusion group to the 0.5-hour-long infusion group to determine whether the longer infusion can cure the infection earlier and whether it is equally safe. The doses are the same in the two groups. Only the duration differs until the patient receives the antibiotic.

Participants will:

  • be given the required antibiotic drug in a 3-hour-long or in a 0.5 hour-long infusion.
  • be examined to make sure their blood drug levels are correct. This will require two blood tests.
  • be treated according to routine care and have examinations and blood tests performed.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

Treatment begins with a short, intermittent infusion of antibiotics. If the patient meets study criteria, randomisation must occur within 24 hours. Prior to enrolment, written informed consent or a declaration of contribution must be signed by the legal guardian and, where age-appropriate, the patient.

Plans for the collection and laboratory evaluation of biological samples:

Per protocol:

This study involves collecting blood samples (200 µl per sample) to monitor drug levels, with each sample identified by the patient's assigned PIN (Personal Identification Number). To ensure measurements reflect steady-state conditions, samples must be collected at least 48 hours after the first post-allocation dose and immediately prior to the next scheduled dose (trough or minimum level). Analysis of free (unbound) drug concentrations is performed via High-Performance Liquid Chromatography (HPLC) with specific absorbance detection for meropenem (290 nm), piperacillin (252 nm), tazobactam (210 nm), and cefepime (263 nm); ceftriaxone is measured using Liquid Chromatography-Mass Spectrometry (LC-MS).

For evaluating the drug levels:

Pathogen minimal inhibitory concentration (MIC) values will be sourced directly from the microbiology laboratory when available; otherwise, values will be retrieved from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) database. In place of a measured MIC, the epidemiological cut-off value (ECOFF)-representing the upper MIC limit for wild-type, non-resistant bacteria-may be used. For empirical dosing where no specific pathogen is identified, the highest MIC for antibiotic-susceptible bacteria will be applied to account for a worst-case scenario.

Standard care:

Routine laboratory assessments-including a complete blood count (CBC) and blood chemistry tests-will be conducted at enrolment and daily thereafter. To ensure accuracy, samples must be analysed within 1-2 hours of collection. Baseline data will include inflammatory markers (C-reactive protein [CRP], procalcitonin [PCT]), hematological parameters (white blood cell count [WBC], platelet count), liver function (liver enzymes and total/direct bilirubin), and serum creatinine. Additionally, clinical severity will be assessed using Paediatric Index of Mortality 3 (PIM-3), Paediatric Risk of Mortality III (PRISM III), and Paediatric Logistic Organ Dysfunction 2 (PELOD 2) scores. While all patients require a pre-antibiotic blood culture, those with negative cultures will be excluded from the microbiological eradication analysis.

In cases where microbiological cultures are negative, the clinician will diagnose infection based on clinical signs and symptoms. These signs and symptoms will also be examined when assessing the clinical response outcome.

Signs of infection may include elevated acute phase proteins (CRP > 10 mg/L or PCT > 0.5 µg/L or WBC > 10,000 /µL), or infection/inflammation confirmed by imaging and any clinical signs (fever > 37.5 °C core temperature or haemodynamic instability - need for inotropic or vasopressor therapy or abnormal blood gas values (normal arterial blood gas values: pH=7.35-7.45, PaO2=80-100 mmHg, PCO2=35-45 mmHg, [HCO3-]=22-28 mEq/L and lactate<3 mmol/L; normal venous blood gas values: pH=7.31-7.41, PvO2=35-45 mmHg, PCO2=41-51 mmHg, [HCO3-]=22-28 mEq/L and lactate<3 mmol/L; normal capillary blood gas values: pH=7.35-7.45, PCO2=35-45 mmHg, [HCO3-]=22-28 mEq/L) or respiratory failure or neurological signs or enteral feeding intolerance.

Criteria for discontinuation or modification of designated interventions:

If blood samples reveal sub-therapeutic antibiotic levels (underexposure), dosing must be adjusted by increasing the dose or the frequency of administration. All adjustments must be documented. Patients requiring these changes will remain in their originally assigned study arm for analysis under the modified intention-to-treat (mITT) population; crossover between study arms is strictly prohibited. In the event of clinician-reported adverse events, the Steering Committee (SC) will determine whether the antibiotic should be discontinued.

If β-lactam therapy must be changed due to clinical deterioration or antibiotic resistance, and the new antibiotic is also a study β-lactam (meropenem, piperacillin/tazobactam, cefepime, or ceftriaxone), the patient remains in the assigned arm (extended infusion [EI] or short-term infusion [SI]) and is not excluded.

All patients are followed for 30 days post-allocation or until discharge or death. For patients discharged before the 30-day mark, a telephone follow-up will be conducted on day 30 to evaluate their clinical status.

Tipo di studio

Interventistico

Iscrizione (Stimato)

110

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Budapest, Ungheria, 1083
        • Reclutamento
        • Pediatric Center (Bókay Street Department), Semmelweis University
        • Contatto:
      • Budapest, Ungheria, 1094
        • Reclutamento
        • Pediatric Center (Tűzoltó Street Department), Semmelweis University
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 1 secondo a 17 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • paediatric patients (0-17 years of age) with suspected or confirmed bacterial infection who are treated in a PICU or NICU and diagnosed with sepsis with a total Phoenix Sepsis Score ≥2 points, and the infection is clinically probable or confirmed by microbiological culture (e.g. from a blood culture, cerebrospinal fluid, urine, trachea, wound, etc.), excluding contamination;
  • who are receiving β-lactams including meropenem, piperacillin/tazobactam, cefepime and ceftriaxone;
  • who received the same β-lactam therapy within 24 hours prior to inclusion or started new β-lactam therapy due to clinical deterioration;
  • written consent of the parent or guardian is obtained.

Exclusion Criteria:

  • palliative care patients;
  • patients participating in other drug trials;
  • patients with impaired renal function if dosing modification is required (estimated Glomerular Filtration Rate [eGFR]<50 mL/min/1.73m2 for meropenem, cefepime, and piperacillin/tazobactam; eGFR<10 mL/min/1.73m2 for ceftriaxone);
  • patients undergoing plasmapheresis (TPE);
  • patients undergoing extracorporeal therapy (continuous kidney replacement therapy [CKRT] or extracorporeal membrane oxygenation [ECMO]);
  • β-lactam allergy;
  • patients admitted from another institution or department who have been on the same β-lactam treatment for more than 24 hours;
  • pregnancy.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: pediatric patients, short-term infusion (P, SI) and neonatal patients, short-term infusion (N, SI)

subset P: 28 days - 17 years subset N: term or pre-term infants < 28 days of post-natal age, or PMA* < 44 weeks

*postmenstrual age

Group short-term infusion (SI):

Duration of infusion is 0.5 hour (h)

Subset paediatric (P):

The doses of beta-lactams are (q…h= every…hours):

- meropenem (MPM): 30 mg/kg or 40 mg/kg for meningitis q8h (max. 2 g q8h)

Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

Group short-term infusion (SI):

Duration of infusion is 0.5 hour (h)

Subset paediatric (P):

The doses of beta-lactams are (q…h= every…hours):

- piperacillin/tazobactam (TZP): 90 mg/kg piperacillin q6h for non-immunosuppressed patients and 100 mg/kg piperacillin q6h for immunosuppressed patients (max. 4.5 g piperacillin/tazobactam per dose)

Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

Group short-term infusion (SI):

Duration of infusion is 0.5 hour (h)

Subset paediatric (P):

The doses of beta-lactams are (q…h= every…hours):

- cefepime (CFP): 30-50 mg/kg q8h or q12h (>1 month: 30 mg/kg every 8-12 hours, 2 months-17 years (bodyweight up to 41 kg): 50 mg/kg every 8-12 hours (max. 2 g per dose; increased dose [q8h] used for severe infection and febrile neutropenia)

Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

Group short-term infusion (SI):

Duration of infusion is 0.5 hour (h)

Subset paediatric (P):

The doses of beta-lactams are (q…h= every…hours):

- ceftriaxone (CTX): 50 mg/kg q12h (max. 4 g per day)

Subset neonatal (N): The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

Sperimentale: pediatric patients, extended infusion (P, EI) and neonatal patients, extended infusion (N, EI)

subset P: 28 days - 17 years subset N: term or pre-term infants < 28 days of post-natal age, or PMA* < 44 weeks

*postmenstrual age

Group extended infusion (EI):

Duration of infusion is 3 hours (h)

Subset paediatric (P):

The doses of beta-lactams are (q…h= every…hours):

- meropenem (MPM): 30 mg/kg or 40 mg/kg for meningitis q8h (max. 2 g q8h)

Subset neonatal (N):

The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

Group extended infusion (EI):

Duration of infusion is 3 hours (h)

Subset paediatric (P):

The doses of beta-lactams are (q…h= every…hours):

- piperacillin/tazobactam (TZP): 90 mg/kg piperacillin q6h for non-immunosuppressed patients and 100 mg/kg piperacillin q6h for immunosuppressed patients (max. 4.5 g piperacillin/tazobactam per dose)

Subset neonatal (N):

The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

Group extended infusion (EI):

Duration of infusion is 3 hours (h)

Subset paediatric (P):

The doses of beta-lactams are (q…h= every…hours):

- cefepime (CFP): 30-50 mg/kg q8h or q12h (>1 month: 30 mg/kg every 8-12 hours, 2 months-17 years (bodyweight up to 41 kg): 50 mg/kg every 8-12 hours (max. 2 g per dose; increased dose [q8h] used for severe infection and febrile neutropenia)

Subset neonatal (N):

The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

Group extended infusion (EI):

Duration of infusion is 3 hours (h)

Subset paediatric (P):

The doses of beta-lactams are (q…h= every…hours):

- ceftriaxone (CTX): 50 mg/kg q12h (max. 4 g per day)

Subset neonatal (N):

The doses of beta-lactams are as recommended by NeoFax® (MerativeTM Micromedex® database), based on postmenstrual age (PMA) and postnatal age.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of patients achieving PK/PD index: 100% fT>MIC (Ctrough >MIC)
Lasso di tempo: two times >48 hours after initiation of antibiotic treatment according to the treatment allocation

In critically ill patients, it is recommended to maintain plasma levels 1-4 times higher than the minimal inhibitory concentration (MIC) of the bacterium isolated throughout the dosing interval (100% fT>1-4×MIC).

The primary outcome for the study will be the proportion of patients achieving therapeutic and optimal drug exposure, defined as plasma concentrations above the MIC for 100% of the dosing interval. Trough plasma concentration levels should be measured. The pharmacokinetic-pharmacodynamic (PK/PD) index used is 100% fT>MIC (Ctrough >MIC).

two times >48 hours after initiation of antibiotic treatment according to the treatment allocation

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of patients achieving PK/PD index: 100% fT>4xMIC (Ctrough >4xMIC)
Lasso di tempo: two times >48 hours after initiation of antibiotic treatment according to the treatment allocation

In critically ill patients, it is recommended to maintain plasma levels 1-4 times higher than the MIC (minimal inhibitory concentration) of the bacterium isolated throughout the dosing interval (100% fT>1-4×MIC).

Trough plasma concentration levels should be measured. The pharmacokinetic-pharmacodynamic (PK/PD) index used is 100% fT>4xMIC (Ctrough >4xMIC).

two times >48 hours after initiation of antibiotic treatment according to the treatment allocation
Time to normalisation of C-reactive protein (CRP)
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

It shows how many days it takes for CRP to return to normal (<10 mg/L).

From enrollment to the end of treatment (maximum 30 days).
Time to normalisation of procalcitonin (PCT)
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

It shows how many days it takes for PCT to return to normal (<0.5 µg/L).

From enrollment to the end of treatment (maximum 30 days).
Time to normalisation of white blood cells (WBC)
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

It shows how many days it takes for WBC to return to normal (<10,000 /µl).

From enrollment to the end of treatment (maximum 30 days).
Microbiological eradication rate
Lasso di tempo: On day 0 before initiation of antibiotic treatment and on days 2, 3 and 5 after initiation of antibiotic treatment

Blood culture must be taken from each patient before starting antibiotic treatment. Additional samples should be taken according to the regimen mentioned below.

On day 0 before initiation of antibiotic treatment and on days 2, 3 and 5 after initiation of antibiotic treatment
Clinical response
Lasso di tempo: Each day from enrollment to the end of treatment (maximum 30 days).

Resolution (or clinical success): disappearance of all signs and symptoms related to the infection.

  • Improvement: a marked or moderate reduction in the severity and/or number of signs and symptoms of infection.
  • Failure: reduction in signs and symptoms of infection is not sufficient to meet the criteria for improvement, which encompasses outcomes such as death or cases where evaluation was not feasible for any reason.
Each day from enrollment to the end of treatment (maximum 30 days).
Time to clinical success or resolution
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

It shows how many days it takes to achieve clinical success or resolution.

From enrollment to the end of treatment (maximum 30 days).
Treatment failure
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

Number of patients for whom the β-lactam antibiotic therapy had to be discontinued due to clinical deterioration and/or antibiotic resistance.

If the newly initiated β-lactam is also among the study β-lactams (meropenem, piperacillin/ tazobactam, cefepime, and ceftriaxone), the patient remains in the originally assigned treatment arm (EI or SI).

From enrollment to the end of treatment (maximum 30 days).
Duration of the antibiotic therapy
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

It shows how many days the antibiotic had to be administered.

From enrollment to the end of treatment (maximum 30 days).
Length of PICU/NICU stay in hours
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

It shows how many hours passed from admission to discharge. PICU=Pediatric Intensive Care Unit NICU=Neonatal Intensive Care Unit

From enrollment to the end of treatment (maximum 30 days).
Length of hospital stay (LOS) in days
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

It shows how many days passed from admission to discharge.

From enrollment to the end of treatment (maximum 30 days).
All-cause mortality
Lasso di tempo: From enrollment to the end of treatment (maximum 30 days).

The total number of deaths from any cause.

From enrollment to the end of treatment (maximum 30 days).
Adverse events (AEs)
Lasso di tempo: Each day from enrollment to the end of treatment (maximum 30 days).

Definition of adverse event: any harmful, undesirable, potentially severe, or life-threatening effects occurring during or after the administration of the antibiotics proposed in this study. They will be collected in a form where all AEs are listed according to the Summary of Product Characteristics (SmPCs).

Each day from enrollment to the end of treatment (maximum 30 days).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 settembre 2026

Completamento primario (Stimato)

31 agosto 2028

Completamento dello studio (Stimato)

31 agosto 2028

Date di iscrizione allo studio

Primo inviato

3 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 marzo 2026

Primo Inserito (Effettivo)

20 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2024-518115-19-02

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

After publication, the IPD that underlie the results will be available upon request in encrypted form, subject to approval by the corresponding author.

Periodo di condivisione IPD

Data will be available immediately following publication with no end date.

Criteri di accesso alla condivisione IPD

Data will be made available to investigators who submit a request for data access for specific aims, subject to approval by the corresponding author. A proposal that describes planned analyses must be submitted to the the corresponding author.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .